Investor Overview

United Health Products, Inc. (UEEC) was formed to develop, produce, and market proprietary wound care products. Our core technology is an absorbable hemostatic gauze that provides the means to quickly control bleeding from open wounds with a cost effective, high efficiency product.

This innovative technology is derived from regenerated oxidized cellulose and is marketed under the trade name HemoStyp®. HemoStyp will produce hemostasis in just seconds when applied to an open wound and is safe and easy to use.

HemoStyp is available in multiple sizes and configurations to suit various market segments and, in a healthcare sector shifting toward high quality care at affordable cost, offers an appealing alternative to higher priced competitive products. In addition to general military and civilian applications, the company has recently introduced Hemostyp to the veterinary, dental surgery, and dialysis markets.

UEEC's CEO, Doug Belpate, has over 30 years of experience in the medical device and wound care sectors. He leads an experienced executive management team with the proven ability to develop, integrate, and grow brands within the healthcare industry.


United Health Products Forms Medical Advisory Board

United Health Products is pleased to announce the formation of an influential and highly regarded Medical Advisory Board. As the company continues to pursue its application to have HemoStyp approved for clinical use in the United States, it looks forward to calling upon these experts in the fields of medicine, veterinary medicine, and dental medicine for guidance and to pursue various opportunities in these different markets. The Board is comprised of Gerard Abate, MD; Joseph M. Chalil, MD, MBA, FACHE; Michael Erik Jessen, MD; I. Richard Massoth, DDS, MSD; David W. Ramey, DVM; and Zachariah P. Zachariah, MD. Please click here for more information on their backgrounds and qualifications.

United Health Products Receives CE Mark Approval for HemoStyp®

United health Products has obtained Class III and CE mark approval for HemoStyp in the European Economic Area (EEA). The EEA comprises the 28 European Union members and a number of other countries.  HemoStyp is now approved for use in internal surgical procedures in more than 30 countries. The approval was received following the provision of all required documentation by the relevant regulatory agencies. The CE marking certifies that a product has met EEA health, safety, and environmental requirements, which ensure consumer safety.

Press Releases
Press Releases 2016-2013 2016 2015 2014 2013    
'SeeThruEquity' Issues Report on United Health Products

Tobin Smith Interviews
CEO Doug Beplate

Investor Relations:

Pan Consultants Ltd.



Keep up to Date and Stay Informed

Sign up to receive company updates, press releases, filings, and special announcements.